26 June 2020

• The ACT-A releases its investment case for $31.3 billion, for its three pillars: COVID-19 vaccines, therapeutics and diagnostics. To date, $3.48 billion has been pledged, leaving a funding gap of $27.9 billion and immediate needs of $17.1 billion. For vaccines, $18.1 billion is needed to produce 2 billion doses by the end of 2021, globally; for therapeutics, $7.2 billion is needed to produce 245 million treatment courses in LMIC in the next 12 months; for diagnostics, $6 billion is needed in the next 12 months for 500 million tests in LMIC. The ACT-A Health Systems Connector has not yet presented its investment case; to date $ 1.7 billion has been pledged. Source
• Hetero announces the launch of Covifor, its generic version of remdesivir; it is priced at a maximun of $72.05 per 100 mg vial. Source

Return to the timeline